Cannara Biotech Inc.
LOVE.V
TSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.70% | 26.34% | 27.49% | 23.90% | 22.42% |
| Total Other Revenue | -- | -- | -- | 66.78% | -28.19% |
| Total Revenue | 35.70% | 26.34% | 27.49% | 24.72% | 21.68% |
| Cost of Revenue | 11.27% | -11.63% | 31.40% | 45.21% | 70.69% |
| Gross Profit | 80.35% | 169.61% | 22.12% | 6.61% | -20.19% |
| SG&A Expenses | 14.19% | -4.91% | 30.68% | 40.55% | 27.56% |
| Depreciation & Amortization | -9.57% | 16.66% | -31.90% | 280.44% | -8.59% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.57% | -10.17% | 28.94% | 44.62% | 54.04% |
| Operating Income | 349.19% | 372.44% | 20.65% | -19.29% | -66.39% |
| Income Before Tax | 177.46% | 228.82% | 42.89% | -20.16% | -31.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 98.41% | 190.28% | 8.60% | 20.91% | -31.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 98.41% | 190.28% | 8.60% | 20.91% | -31.21% |
| EBIT | 349.19% | 372.44% | 20.65% | -19.29% | -66.39% |
| EBITDA | 164.79% | 1,268.20% | 12.41% | -10.41% | -47.88% |
| EPS Basic | 95.15% | 189.82% | 8.77% | 24.53% | -30.67% |
| Normalized Basic EPS | 28,300.00% | 227.93% | 42.99% | -21.82% | -100.67% |
| EPS Diluted | 93.20% | 185.91% | 27.40% | 20.00% | -33.48% |
| Normalized Diluted EPS | 27,900.00% | 225.70% | 42.45% | -23.18% | -100.68% |
| Average Basic Shares Outstanding | 1.57% | 0.60% | -0.22% | -2.83% | -0.72% |
| Average Diluted Shares Outstanding | 1.18% | 2.48% | 0.62% | -1.20% | 0.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |